Our first product, RLV-113, is a drug-device combination product that will be first-in-class for the 500,000 patients in the U.S. that suffer from a disease but do not respond to the class of drugs available for self-administration. RLV-113 will enable patients to take this medicine wherever they are without having to make a special trip to a clinic for administration. Relevale licensed RLV-113 to a pharmaceutical company with experience in the space for development and commercialization.
